Ultime notizie per Waton Financial (NASDAQ:WTF) Azioni

Waton Financial Ltd is a holding company that operates its business through subsidiaries in the securities brokerage and distribution services, margin financing services, and other ancillary services business; Software licensing and related support services, including licensing of trading platform applications, upgrades and enhancements, maintenance; and other associated services to securities brokers and financial institutions. The group also provided software licensing and related support services, including licensing trading platform applications, and others.

Wall Street New York Stock Exchange

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

SWKH

L&#39;indicatore RSI sotto 30 segnala opportunità su azioni sottovalutate. Focus su 3 nomi dopo i recenti cali e news societarie specifiche.

3 titoli finanziari in territorio ipervenduto che potrebbero decollare nel Q2

Waton Financial Limited - Ordinary Shares

Waton Financial Ltd

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">94.80</td>
<td align="right">0.44</td>
<td align="right">0.46</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.14</td>
<td align="right">0.12</td>
<td align="right">0.24</td>
<td>141.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.87</td>
<td align="right">0.03</td>
<td align="right">0.03</td>
<td>1.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">208.13</td>
<td align="right">-0.34</td>
<td align="right">-0.17</td>
<td>16.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.86</td>
<td align="right">-0.19</td>
<td align="right">-0.14</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">82.30</td>
<td align="right">-0.09</td>
<td align="right">-0.11</td>
<td>9.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Movers

ETFs

Leading And Lagging Sectors For April 28, 2025

Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) shares are trading higher premarket on Monday. The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 billion.
Net sales <a target="_blank" href="https://www.cemex.com/w/cemex-reports-record-first-quarter-net-income-new-ceo-with-strong-commitment-to-bolster-shareholder-return" rel="noreferrer noopener">fell </a>7% year over year (Y/Y), mainly due to lower volumes in Mexico.
Mexico sales declined 25% Y/Y to $981 million, United States sales fell 4% Y/Y to $1.19 billion, Europe, Middle East, and Africa rose 2% Y/Y to $1.07 billion, and South, Central America, and the Caribbean increased 2% Y/Y to $314 million.
EBITDA declined 18% Y/Y to $601 million in the quarter, with a margin contracted 2.0ppt Y/Y to 16.5% in the quarter.
Lower volumes and weather-related maintenance activity impacted the EBITDA margin.
Segment-wise, operating EBITDA fell 27% Y/Y in Mexico, 20% Y/Y in the United States and 3% Y/Y in South and Central America and the Caribbean, while it increased 40% Y/Y in Europe, the Middle East and Africa segment.
Outlook: Cemex expects recurrent yearly EBITDA savings of at least $150 million in<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> 2025 and $350 million by 2027</a>.
Given the macroeconomic uncertainties and anticipated savings from Project Cutting Edge, the company continues to forecast flat EBITDA performance <a href="https://www.cemex.com/documents/d/cemex/1q25-presentation-english" target="_blank" rel="noreferrer noopener">for </a>2025.
Cemex remained optimistic about volume growth in EMEA and SCAC, anticipates improved performance in Mexico, and expects stable market conditions in the U.S. during the second half of 2025.
The company projects FCF to deliver $500 million in savings in 2025.
Price Action: CX shares are up 2.53% at $6.070&nbsp;premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45029247/unitedhealth-t-mobile-and-fiserv-are-among-top-12-large-cap-losers-last-week-apr-21-apr-25-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?</a></li>
</ul>

Equities

Mid Cap

Guidance

Cemex's Q1 Results Show Strong EMEA Growth, Offset by Mexican Market Struggles

Wedbush analyst Jay McCanless upgrades Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) from Neutral to Outperform and raises the price target from $38 to $43.

Upgrades

Price Target

Analyst Ratings

Wedbush Upgrades Tri Pointe Homes to Outperform, Raises Price Target to $43

Mizuho analyst Ben Chaiken maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Outperform and lowers the price target from $62 to $59.

DKNG

Mizuho Maintains Outperform on DraftKings, Lowers Price Target to $59

Barclays analyst Luke Sergott maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Overweight and lowers the price target from $18 to $15.

AVTR

Barclays Maintains Overweight on Avantor, Lowers Price Target to $15

<ul>
<li>Success milestone reached in Scribe and Prevail's ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe's CRISPR technology</li>
<li>Companies to jointly present new preclinical data on self-inactivating AAV (siXAAV) technology from their collaboration at the 28th ASGCT Annual Meeting</li>
</ul>
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the achievement of a success milestone for one of the targets in its research collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular disorders. The success milestone marks Scribe's second such partnership achievement in 2025.
At the 28th American Society of Gene &amp; Cell Therapy (ASGCT) Annual Meeting, the companies will have a joint presentation titled "Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS." The presentation will take place during the poster reception between 5:30 and 7:00 p.m. CT on Thursday, May 15, 2025, at the New Orleans Ernest N. Morial Convention Center.

Scribe Therapeutics And Prevail To Present New Preclinical Data On siXAAV Technology From Collaboration At ASGCT Annual Meeting

Mizuho analyst Gabriel Moreen downgrades Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) from Outperform to Neutral and lowers the price target from $165 to $164.

Downgrades

Mizuho Downgrades Atmos Energy to Neutral, Lowers Price Target to $164

Barclays analyst Benjamin Budish maintains Virtus Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>) with a Underweight and raises the price target from $149 to $150.

VRTS

Barclays Maintains Underweight on Virtus Inv, Raises Price Target to $150

CHKP

Check Point Software Achieves FedRAMP "In Process" Milestone

As of April 28, 2025, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Huntington Ingalls Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>)</h3>
<ul>
<li>On April 11, Goldman Sachs analyst Noah Poponak upgraded the rating for Huntington Ingalls Indus from Sell to Buy and raised the price target from $145 to $234. The company's stock jumped around 10% over the past month and has a <a href="https://www.benzinga.com/quote/HII">52-week high of $285.81</a>.</li>
<li>RSI Value: 71.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>HII Price Action: Shares of Huntington Ingalls gained 1.9% to close at $226.05 on Friday.</li>
<li>Edge Stock Ratings: 30.06 Momentum score with Value at 60.22. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/hii"><img loading="lazy" decoding="async" width="491" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189.png" alt="" class="wp-image-890630" style="width:366px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189.png 491w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28072532/image-189-300x117.png 300w" sizes="(max-width: 491px) 100vw, 491px" /></a></figure>
<h3 class="wp-block-heading">Insteel Industries Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>)</h3>
<ul>
<li>On April 17, the company posted better-than-expected quarterly sales. &#8220;We are encouraged by the strengthening demand for our products that began during our first quarter,&#8221; said H.O. Woltz III, President and CEO of Insteel. &#8220;The positive momentum we experienced through our second fiscal quarter was driven by improving business conditions and rising customer confidence, trends that are not fully reflected in the broader macroeconomic indices generally used to measure the strength of the construction industry. It is important to note that our results, and my comments, reflect conditions we experienced prior to the recent turmoil created by the changing tariff policy of the Trump Administration. &#8221; The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/IIIN">has a 52-week high</a> of $35.52.</li>
<li>RSI Value: 71</li>
<li>IIIN Price Action: Shares of Insteel Industries fell 0.5% to close at $33.00 on Friday.</li>
</ul>
Unlock the rest of the BZ Edge Rankings and see <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how top stocks stack up</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

IIIN

Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRTS#NASDAQ">DRTS</a>, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT&#xAE;, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.&nbsp;&nbsp;
The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau intends to use the net proceeds from the offering for general corporate purposes, including research and development-related purposes in connection with its product candidates, for expansion of its manufacturing capabilities and for potential commercialization of its product candidates.

DRTS

ORMP

Oramed Pharma Closes Strategic Investment In Alpha Tau Medical; Oramed Affiliate Purchases About 14.1M Alpha Tau's Ordinary Shares $2.612/Shr

NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/NXPI/earnings">closing bell on Monday, April 28.</a>
Analysts expect the Eindhoven, the Netherlands-based company to report quarterly earnings at $2.60 per share, down from $3.24 per share in the year-ago period. NXP Semiconductors projects to report quarterly revenue at $2.83 billion, compared to $3.13 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 11, NXP Semiconductors launched its new S32K5 series of automotive microcontrollers (MCU).
NXP Semiconductors shares slipped 0.01% to close at $193.55 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Blayne Curtis maintained an Overweight rating and cut the price target from $230 to $190 on April 22, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Stifel analyst Tore Svanberg maintained a Hold rating and slashed the price target from $210 to $170 on April 17, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Citigroup analyst Christopher Danely maintained a Buy rating and slashed the price target from $290 to $220 on April 11, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Mizuho analyst Vijay Rakesh maintained an Outperform rating and increased the price target from $240 to $255 on Feb. 20, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Truist Securities analyst William Stein maintained a Buy rating and raised the price target from $245 to $258 on Feb. 18, 2025. This analyst has an accuracy rate of 82%.</li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="615" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-1024x615.png" alt="" class="wp-image-890283" style="width:547px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-1024x615.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184-768x461.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28033532/image-184.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

NXPI

Top Wall Street Forecasters Revamp NXP Semiconductors Expectations Ahead Of Q1 Earnings

Barclays analyst David Anderson maintains Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Overweight and lowers the price target from $11 to $8.

PTEN

Barclays Maintains Overweight on Patterson-UTI Energy, Lowers Price Target to $8

LTRY

Lottery.com Announces Company Update; Says Is Focused On Increasing Revenues Through Resuming Gaming Operations And Monetizing Sports.com And Completing Certain Acquisitions That Will Accelerate Profitability And Shareholder Value

Management

WestCX Appoints Sam Meckey As President; Effective Immediately

&nbsp;LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) (the "Company"), a provider of personal emergency response systems (PERS), health communication devices, and technology for the growing care economy, today announced changes to its Board committee assignments.
The LogicMark Board of Directors maintains an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. The Board comprises four independent non-executive directors who serve on the Committees and the Company's Chief Executive Officer (CEO), totaling five directors.
The following new Board committee assignments reflect LogicMark's ongoing efforts to ensure that its Board effectively supports the Company's strategic direction and operational footprint.
Key updates include:
Carine Schneider, a director since October 2023, has been appointed Board Chair and remains a member of the Compensation Committee. She has helped grow B2B companies across multiple channels within capital markets, SaaS providers, and advisory services, utilizing AI and blockchain technology. She is the former President of Nasdaq Private Market and CEO of SaaS company Certent.
John Pettitt, who has served as a Director since March 2022, has been appointed Chair of the Nominating and Corporate Governance Committee. He continues to serve as a member of the Audit and Compensation Committees. John is a technology leader at Google with deep software and e-commerce expertise and a seasoned entrepreneur, having founded, edited, and IPO'd several companies.
Robert Curtis, a Director since July 2018, has been named Chair of the Compensation Committee, supported by Directors Schneider and Pettitt. He will continue to serve on the Audit Committee. He is a seasoned life sciences executive and strategic advisor with over 30 years of experience leading biotech and healthcare organizations, specializing in early-stage company development, scientific innovation, and strategic growth.
Barbara Gutierrez was appointed to the Board in May 2022 and remains Chair of the Audit Committee and is the Board's designated financial expert. She is a Certified Public Accountant and Chartered Management Accountant. Directors Pettitt and Curtis support her on the Audit Committee. Barbara is the CFO of Nasdaq-listed Modivcare and a highly accomplished board advisor with 30+ years of experience leading IPOs, complex financings, and growth strategies for public companies across the healthcare and technology sectors.
Chia-Lin Simmons, CEO of LogicMark and executive Board member since June 2021, continues to lead the Company's daily operations and does not serve on Board committees in line with governance best practices. Her extensive experience includes 30 years in the technology industry, including executive roles at Google, Audible / Amazon, and Harman International, and founding AI startup LookyLoo, reflecting her deep expertise in AI, IoT, and SaaS.
Carine Schneider, Board Chair, commented, "It's an honor to continue serving as part of the LogicMark Board as we help shape the Company's evolution into a leading-edge technology platform. This transformation, driven by our strategic focus on AI and machine learning, the launch of groundbreaking solutions like the Freedom Alert Max and the Aster App, and the value of our growing patent portfolio comprising 37 patents, 23 of which have been issued, and 17 currently filed since 2021, reflect our commitment to innovation and impact. As we redefine the customer experience and deepen our presence in the growing care economy, LogicMark is poised to thrive in the promising future of connected care." &nbsp;

LGMK

LogicMark Announces Changes To Board

American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.4, a high estimate of $37.00, and a low estimate of $34.00. Observing a 4.89% increase, the current average has risen from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845265_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive American Healthcare REIT is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joe Dickstein &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $37.00&#x7C;- &#x7C; 
&#x7C;Austin Wurschmidt &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $34.00&#x7C;$35.00 &#x7C; 
&#x7C;Ronald Kamdem &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $37.00&#x7C;$36.00 &#x7C; 
&#x7C;Michael Carroll &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $34.00&#x7C;$34.00 &#x7C; 
&#x7C;Aaron Hecht &#x7C;Citizens Capital Markets&#x7C;Raises &#x7C;Market Outperform&#x7C; $35.00&#x7C;$30.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to American Healthcare REIT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Healthcare REIT compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for American Healthcare REIT's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of American Healthcare REIT's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on American Healthcare REIT analyst ratings.</a>
<h2>Delving into American Healthcare REIT's Background</h2>
American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. It has four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of its revenue through Integrated Senior Health Campuses segment.
<h3>Understanding the Numbers: American Healthcare REIT's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: American Healthcare REIT displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 12.47%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: American Healthcare REIT's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): American Healthcare REIT's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.42%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): American Healthcare REIT's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.69%, the company may face hurdles in achieving optimal financial performance.
Debt Management: American Healthcare REIT's debt-to-equity ratio is below the industry average at 0.83, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About American Healthcare REIT Stock

In the last three months, 7 analysts have published ratings on Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Kontoor Brands and provided 12-month price targets. The average target is $89.71, accompanied by a high estimate of $108.00 and a low estimate of $69.00. This current average represents a 9.12% decrease from the previous average price target of $98.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845256_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Kontoor Brands. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $69.00&#x7C;$93.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $72.00&#x7C;$83.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $90.00&#x7C;$100.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $96.00&#x7C;$108.00 &#x7C; 
&#x7C;Paul Kearney &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $93.00&#x7C;$100.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $100.00&#x7C;$95.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$112.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kontoor Brands. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kontoor Brands compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kontoor Brands's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Kontoor Brands's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KTB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kontoor Brands analyst ratings.</a>
<h2>About Kontoor Brands</h2>
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
<h3>Kontoor Brands: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Kontoor Brands showcased positive performance, achieving a revenue growth rate of 4.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Kontoor Brands's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 16.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kontoor Brands's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.98.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Kontoor Brands: Insights From 7 Financial Analysts

Across the recent three months, 7 analysts have shared their insights on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.57, with a high estimate of $80.00 and a low estimate of $36.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $67.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Announces &#x7C;Buy &#x7C; $64.00&#x7C;- &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Richard Law &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$42.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Kristen Kluska &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $67.00&#x7C;$67.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Celldex Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -71.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -4007.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -6.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDX

Analyst Expectations For Celldex Therapeutics's Future

MicroAlgo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NYSE">MLGO</a>) short percent of float has fallen 50.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 21.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>MicroAlgo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745845229_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MicroAlgo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MicroAlgo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MicroAlgo's peer group average for short interest as a percentage of float is 3.88%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

MLGO

How Do Investors Really Feel About MicroAlgo?

IPOs

Press Releases

Waton Financial Limited Announces Pricing of Initial Public Offering

Waton Financial Limited Announces Closing of Initial Public Offering with Simultaneous Full Exercise of the Over-Allotment Option

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares

AMTD IDEA

BGC Group

Dominari Holdings

Evercore

Garden Stage

Lazard

Lion Group Holding Ltd. - American Depositary Share

Lion Group Holding

Moelis

MDB Capital Holdings, LLC - Class A common

MDB Capital Holdings

Magic Empire Global Limited - Class A Ordinary Shares

Magic Empire Glb

mF International Limited - Class A Ordinary Shares

mF International

Marex Group

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

Piper Sandler

PJT Partners

Plutus Financial Group Limited - Ordinary Shares

Plutus Financial Group

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

B. Riley Financial

Siebert Finl

StoneX Group

Solowin Holdings - Class A Ordinary Share

Solowin Holdings

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

Comments

Waton Financial

Notizie

Ultime notizie per Waton Financial (NASDAQ:WTF) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO